Activating mutations in AKT1–3 are relatively rare in prostate cancer, while gene amplification has been observed in up to 4.5% (AKT1), 2% (AKT2), and 4.7% (AKT3) of prostate cancer cases, respectively [144]. Here, AKT2 is linked to prostate cancer.